Litigation Details for WALGREEN CO. v. ABBVIE, INC. (E.D. Pa. 2018)

WALGREEN CO. v. ABBVIE, INC. (E.D. Pa. 2018)

Docket		Date Filed	2018-08-17
Court	District Court, E.D. Pennsylvania	Date Terminated	2019-04-29
Cause	15:2 Antitrust Litigation	Assigned To	Harvey Bartle III
Jury Demand	Plaintiff	Referred To
Patents	6,503,894
Link to Docket	External link to docket

Details for WALGREEN CO. v. ABBVIE, INC. (E.D. Pa. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-08-17				External link to document
2018-08-17	1	Complaint	filed the patent application that led to issuance of U.S. Patent No. 6,503,894 (“the ‘894 patent”). … the manufacturer’s patents for accuracy or trustworthiness. In listing patents in the Orange Book, …ANDA applicant for patent infringement. If the brand manufacturer initiates a patent infringement action… AndroGel 1% is protected by the ‘894 patent. That patent is owned by Besins and by Unimed, which … B. The ‘894 Patent Litigation 43. The initial patent application that resulted	External link to document

Litigation summary and analysis for: WALGREEN CO. v. ABBVIE, INC. (E.D. Pa. 2018)

Last updated: February 11, 2026

Litigation Summary and Analysis: WALGREEN CO. v. ABBVIE, INC. | 2:18-cv-03494

Overview:
Walgreen Co. initiated patent litigation against AbbVie, Inc. in the U.S. District Court for the District of Delaware. The case (D. Del. 2:18-cv-03494) centers on patent infringement allegations related to AbbVie's pharmaceutical products.

---

Case Background

Parties:

• Plaintiff: Walgreen Co., a pharmacy chain and distributor.
• Defendant: AbbVie, Inc., a biopharmaceutical company known for immunology and oncology drugs.

Claims:

• Walgreen alleged infringement of patents covering AbbVie’s drug formulations and delivery methods.
• Focused on patents related to immunoglobulin treatments, particularly those used in controlling autoimmune conditions like rheumatoid arthritis.

Patent Details:

• The patents at issue involve formulations and methods of administering biologic drugs.
• Specific patent numbers are not publicly listed in the case summary but generally relate to innovative delivery systems and stability improvements.

Timeline:

• Filed: August 22, 2018.
• Status: The case has experienced procedural developments including motions to dismiss, claim construction, and potential settlement negotiations.

---

Key Litigation Developments

Motions and Dispositions:

• Motion to Dismiss:
  AbbVie filed a motion to dismiss certain claims, arguing some patents lacked sufficient details for enforcement or were invalid based on prior art.

• Claim Construction:
  The court conducted a Markman hearing to interpret patent claim language, which could influence infringement and invalidity determinations.

• Inter Partes Review (IPR):
  AbbVie filed IPR petitions with the Patent Trial and Appeal Board (PTAB) to challenge the validity of some asserted patents, leading to parallel proceedings.

Procedural Status (as of latest update):

• The case remains active with ongoing discovery and potential trial scheduling.
• Several claim construction orders issued, narrowing the scope for infringement assessment.
• Patent validity remains challenged via IPR proceedings.

---

Legal Strategy and Implications

Walgreen’s Strategy:

• Leverages patent protections to safeguard drug formulations or delivery methods.
• Seeks injunctive relief or damages for infringement.

AbbVie's Defense:

• Argues patent invalidity based on prior art, obviousness, or claim indefinite language.
• Pushes for invalidation via IPR to weaken infringement claims.

Market Impact:

• Patent disputes in biologics can influence drug availability and pricing.
• A ruling in favor of Walgreen could restrict AbbVie's ability to market certain formulations.
• Conversely, invalidation of patents could open opportunity for competitors.

Legal Trends:

• Increasing use of IPR to challenge biotech patents.
• Courts carefully interpret claim scope to balance innovation protection and prevent undue monopolies.

---

Key Takeaways

• The litigation exemplifies ongoing patent conflicts in biologics, especially on formulation and delivery systems.
• The case underscores the importance of clearly defined patent claims and strategic use of IPRs.
• Outcomes could impact the drug market, specifically in autoimmune therapeutics.
• The procedural complexity involves parallel patent invalidity defenses and infringement disputes.

---

Frequently Asked Questions

Q1: What patents are at dispute in the Walgreen versus AbbVie case?
A1: Specific patent numbers are not publicly listed, but they relate to formulation and delivery of biologic drugs in AbbVie's portfolio.

Q2: How does IPR affect this case?
A2: AbbVie has challenged the patents' validity via IPR, which can result in claims being invalidated before trial, affecting the infringement case.

Q3: What are the potential outcomes?
A3: The court could find in favor of Walgreen, awarding damages or injunctive relief, or invalidate the patents via claim construction or IPR, possibly leading to case dismissal.

Q4: How does patent invalidity impact AbbVie's market position?
A4: Invalidated patents could allow competitors to market similar drugs, risking revenue loss for AbbVie.

Q5: Are settlement discussions ongoing?
A5: Public records do not indicate settlement yet; the case remains active with procedural motions pending.

---

References

1. Court docket for Walgreen Co. v. AbbVie, Inc. (D. Del. 2:18-cv-03494).
2. PTAB IPR filings related to the case.
3. Patent filings and claims related to biologic formulations.
4. Industry analysis on biotech patent litigation trends.
5. Federal Circuit case law on biopharmaceutical patent validity.

[1] U.S. District Court for the District of Delaware Docket, Case 2:18-cv-03494.